Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;65(13-14):1667-85.
doi: 10.1016/j.addr.2013.09.014. Epub 2013 Oct 8.

Nanocarriers for delivery of platinum anticancer drugs

Hardeep S Oberoi  1 , Natalia V Nukolova, Alexander V Kabanov, Tatiana K Bronich
Affiliations
Review

Nanocarriers for delivery of platinum anticancer drugs

Hardeep S Oberoi et al. Adv Drug Deliv Rev. 2013 Nov.

Abstract

Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum-polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.

Keywords: 5-FU; 5-fluorouracil; BIC; Block ionomer complex; CDDP; CMC; CTR1; DACHPt; DMPG; DPPG; Dendrime; Drug delivery systems; HPGs; HPMA; Liposome; MWCNTs; Micelle; N-(2-hydroxypropyl)methacrylamide; NDDP; NSCLC; Nanoparticle; Nanotube; OCTs; PAMAM; PAsp; PEG; PEG-b-(polymethacrylic acid); PEG-b-PCL; PEG-b-PMAA; PEG-b-polycaprolactone; PGlu; PIC; Platinum drugs; Polymer conjugate; RES; SCLC; SPC-3; SWCNTs; block ionomer complexes; cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II); cis-dichloro(1,2-diamminocyclohexane) platinum (II); cisplatin; copper transporter 1; critical micelle concentration; dimyristoyl phosphatidylglycerol; dipalmitoyl phosphatidylglycerol; hyperbranched polyglycerols; multi-walled carbon nanotubes; non-small cell lung cancer; organic cation transporters; poly(aspartic acid); poly(glutamic acid); polyamidoamines; polyethylene glycol; polyion complex; reticuloendothelial system; single-walled carbon nanotubes; small cell lung cancer; soy phosphatidylcholine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic illustration of cellular accumulation of cisplatin, its intracellular aquation, activation of cellular signaling pathways by platinum induced DNA damage and the resultant cell death.
Fig. 2
Fig. 2
Various therapeutic macromolecular carriers for platinum drug delivery currently under preclinical and clinical development.
Fig. 3
Fig. 3
Schematic illustration of conventional, ‘stealth’ and targeted liposomal platforms for platinum drug delivery. Liposomes can be made ‘stealth’ by incorporation of PEG-conjugated phospholipids or by incorporation of PEG containing polymers such as Pluronics. Further conjugation of a targeting ligand can be achieved by using a functionalized PEG chain.
Fig. 4
Fig. 4
Chemical structures of polymer–platinum conjugates.
Fig. 5
Fig. 5
Schematic illustration of polymer micelle platforms for platinum drug delivery.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–699. - PubMed
    1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–386. - PubMed
    1. Higby DJ, Wallace HJ, Jr, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974;33:1219–1225. - PubMed
    1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573–584. - PubMed
    1. Gordon M, Hollander S. Review of platinum anticancer compounds. J Med. 1993;24:209–265. - PubMed

Publication types

MeSH terms